EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes

Ignatios Ikonomidis iD, George Pavlidis iD, Loukia Pliouta, Konstantinos Katogiannis iD, Eirini Maratou iD, John Thymis iD, Eleni Michalopoulou, Vasiliki Prentza, Eleni Katsanaki iD, Dimitrios Vlachomitros, Aikaterini Kountouri iD, Emmanouil Korakas iD und 4 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.039129 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Ignatios Ikonomidis und 15 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Cardiology, School of Medicine University General Hospital "Attikon", National and Kapodistrian University of Athens Greece. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Glucosides, Hypoglycemic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We investigated the effects of the combined treatment with glucagon like peptide‐1 receptor agonists (GLP‐1RA) and sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) on NT‐proBNP (N‐terminal pro‐brain natriuretic peptide), GDF‐15 (growth differentiation factor 15), and MOTS‐c (mitochondrial‐derived peptide‐c) in patients with type 2 diabetes (T2D) and high or very high cardiovascular risk.

Methods

We studied 163 consecutive patients with type 2 diabetes who were treated with insulin (n=40), liraglutide (n=41), empagliflozin (n=42), or their combination (GLP‐1RA+SGLT‐2i) (n=40) and were matched using propensity score analysis. We measured the following at baseline and 4 and 12 months of treatment: (1) NT‐proBNP, GDF‐15, and MOTS‐c; (2) 2,2′‐azino‐bis(3‐ethylbenzothiazoline‐6‐sulfonic acid), and (3) left ventricular global longitudinal strain, left atrial strain during atrial reservoir phase, and global work index using speckle‐tracking imaging.

Results

At 12 months, GLP‐1RA, SGLT‐2i, and their combination showed a greater reduction of NT‐proBNP (−43.1% versus −54.2% versus −56.9% versus −14.7%) and GDF‐15 than insulin. Only treatment with SGLT‐2i and GLP‐1RA+SGLT‐2i improved MOTS‐c. GLP‐1RA, SGLT‐2i, or GLP‐1RA+SGLT‐2i provided an increase of global longitudinal strain, left atrial strain, and global work index compared with insulin. In all patients, the reduction of NT‐proBNP was associated with the improvement of global longitudinal strain, left atrial strain during atrial reservoir phase, and global work index; the decrease of GDF‐15 with the increase of ABTS and MOTS‐c; and the increase of MOTs‐c with improved global longitudinal strain and constructive myocardial work at 12 months ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsGlucosidesHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedBenzhydryl CompoundsBiomarkersDrug Therapy, CombinationGrowth Differentiation Factor 15InsulinLiraglutideNatriuretic Peptide, BrainPeptide FragmentsTreatment Outcome

Stichwörter der Autor:innen

N‐terminal pro‐brain natriuretic peptideglucagon like peptide‐1 receptor agonistsgrowth differentiation factor 15mitochondrial‐derived peptide‐csodium‐glucose cotransporter‐2 inhibitors

Substanzen

Benzhydryl CompoundsBiomarkersempagliflozinGDF15 protein, humanGlucagon-Like Peptide-1 Receptor AgonistsGlucosidesGrowth Differentiation Factor 15Hypoglycemic AgentsInsulinLiraglutide

Autor:innen und Institutionen

  • 2nd Department of Cardiology, School of Medicine University General Hospital "Attikon", National and Kapodistrian University of Athens Greece.
  • 2nd Propaedeutic Department of Internal Medicine, Research Unit and Diabetes Center, School of Medicine University General Hospital "Attikon", National and Kapodistrian University of Athens Athens Greece.
  • Laboratory of Clinical Biochemistry, School of Medicine University General Hospital "Attikon", National and Kapodistrian University of Athens Athens Greece.
  • Laboratory of Pharmacology, Faculty of Pharmacy National and Kapodistrian University of Athens Athens Greece.
  • Department of Biochemistry and Biotechnology University of Thessaly Larissa Greece.

ORCID-Profile: Ignatios Ikonomidis, George Pavlidis, Konstantinos Katogiannis, Eirini Maratou, John Thymis, Eleni Katsanaki, Aikaterini Kountouri, Emmanouil Korakas

Zitieren

APA

Ikonomidis, I., Pavlidis, G., Pliouta, L., Katogiannis, K., Maratou, E., Thymis, J., Michalopoulou, E., Prentza, V., Katsanaki, E., Vlachomitros, D., Kountouri, A., Korakas, E., Andreadou, I., Kouretas, D., Parissis, J., & Lambadiari, V. (2025). Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.039129

Vancouver

Ikonomidis I, Pavlidis G, Pliouta L, Katogiannis K, Maratou E, Thymis J, et al. Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.039129

BibTeX
@article{Ikonomidis2025,
  author = {Ikonomidis, Ignatios and Pavlidis, George and Pliouta, Loukia and Katogiannis, Konstantinos and Maratou, Eirini and Thymis, John and Michalopoulou, Eleni and Prentza, Vasiliki and Katsanaki, Eleni and Vlachomitros, Dimitrios and Kountouri, Aikaterini and Korakas, Emmanouil and Andreadou, Ioanna and Kouretas, Dimitrios and Parissis, John and Lambadiari, Vaia},
  title = {Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.039129}
}
Kostenlos starten →